Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 211 AL 225

Small molecule-mediated therapeutic approaches to target Tau and Alzheimer's disease

Chinnathambi S.

Adv Protein Chem Struct Biol. 2025;145:287-304. doi: 10.1016/bs.apcsb.2024.11.010. Epub 2024 Dec 5.

The involvement of the cholinergic system in Alzheimer disease

Cuello AC.

Handb Clin Neurol. 2025;211:63-79. doi: 10.1016/B978-0-443-19088-9.00005-6.

Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption

Schott JM, Marshall CR.

Arq Neuropsiquiatr. 2025 May;83(5):1-4. doi: 10.1055/s-0045-1807718. Epub 2025 May 9.

Mouse models of Anti-Aβ immunotherapies

Pikus P, Turner RS, Rebeck GW.

Mol Neurodegener. 2025 May 13;20(1):57. doi: 10.1186/s13024-025-00836-x.

Are we missing a trick by not exploiting fruit flies in inflammation-led drug discovery for neurodegeneration?

Price R, Ramirez-Moreno M, Cooper A, Singh R, Ming Khaw Y, Mudiwa Mhaka A, Sivanantharajah L, Mudher A.

Expert Opin Drug Discov. 2025 Jun;20(6):721-734. doi: 10.1080/17460441.2025.2498675. Epub 2025 May 19.

Therapeutic potential of dual HDAC6/SIRT2 inhibition in Alzheimer's disease

Wang X, Li C, Chen L, He B, Li Y.

Eur J Med Chem. 2025 Sep 15;294:117733. doi: 10.1016/j.ejmech.2025.117733. Epub 2025 May 9.

Nano-Chaperones: Bridging Therapeutics for Amyloid Aggregation in Alzheimer's Disease and Type-2 Diabetes Mellitus

Siddiqui F, Mishra P, Khanam S, Ranjan S, Alam P, Albalawi T, Khan S, Mir SS.

Eur J Neurosci. 2025 May;61(10):e70142. doi: 10.1111/ejn.70142.

Advances in Alzheimer's therapy: Exploring neuropathological mechanisms to revolutionize the future therapeutic landscape

Sugandhi VV, Gadhave DG, Ugale AR, Kulkarni N, Nangare SN, Patil HP, Rath S, Saxena R, Lavate A, Patel AT, Jadhav A, Paudel KR.

Ageing Res Rev. 2025 Jul;109:102775. doi: 10.1016/j.arr.2025.102775. Epub 2025 May 20.

The NLRP3-P2X7 Axis and Cytokine Crosstalk in Alzheimer's Disease: Mechanisms, Implications, and Therapeutic Opportunities

Kurmi S, Doshi G, Parab SB.

CNS Neurol Disord Drug Targets. 2025;24(11):795-822. doi: 10.2174/0118715273377780250505115039.

Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease

Sehlin D, Hultqvist G, Michno W, Aguilar X, Dahlén AD, Cerilli E, Bucher NM, Lopes van den Broek S, Syvänen S.

J Prev Alzheimers Dis. 2025 Sep;12(8):100214. doi: 10.1016/j.tjpad.2025.100214. Epub 2025 May 26.

Targeting the JAK/STAT3/SOCS signaling pathway in Alzheimer's disease

Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Saad HM, Al-Gareeb AI, Albuhadily AK.

Inflammopharmacology. 2025 Jun;33(6):2951-2962. doi: 10.1007/s10787-025-01796-w. Epub 2025 Jun 3.

MRI protocols and sequences for amyloid-related imaging abnormalities monitoring in Alzheimer's disease patients treated with monoclonal antibodies

Agosta F, Cecchetti G, Spinelli EG, Ghirelli A, Rugarli G, Filippi M.

Curr Opin Neurol. 2025 Aug 1;38(4):289-297. doi: 10.1097/WCO.0000000000001388. Epub 2025 Jun 4.

Bioactive compound nanoparticles for Alzheimer's disease

Kshirsagar N, Patil A, Suryawanshi M.

Inflammopharmacology. 2025 Jun;33(6):2963-2976. doi: 10.1007/s10787-025-01801-2. Epub 2025 Jun 5.

Interlinking diabetes and Alzheimer's disease: A pathway through medicinal plant-based treatments

Pattanaik SK, Anil PM, Jena S, Rath D.

J Ethnopharmacol. 2025 Jul 24;351:120092. doi: 10.1016/j.jep.2025.120092. Epub 2025 Jun 6.

Alzheimer's Disease: A Review of Molecular Mechanisms and Therapeutic Implications by Targeting Sirtuins, Caspases, and GSK-3

Pandya K, Roul K, Tripathi A, Belemkar S, Sinha A, Erol M, Kumar D.

ACS Chem Neurosci. 2025 Jun 18;16(12):2178-2195. doi: 10.1021/acschemneuro.5c00207. Epub 2025 Jun 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias